Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Phase 3 clinical trials recorded an average of 28.7% body weight reduction at 68 weeks roughly 71 pounds alongside a 75.8% reduction in knee osteoarthritis pain scores
The benchmark to evaluate at week 12 is whether you have achieved at least 5% body weight loss from your starting point
While some people respond to taking a very small dose called super responders others cannot tolerate moving up to the next higher standard dose and need something in between. This helps explain why one recent study among patients with diabetes found that microdosing helped them stick with their GLP-1s, reducing side effects without compromising efficacy
Similar to a previous clinical study [18], these peptides significantly reduced lean mass, indicating that these GLP-1 analog peptides suppressed both fat and lean mass (Fig
Although an association with urinary congenital malformations was identified, it was based on limited unadjusted data and may reflect confounding by maternal diabetes or obesity rather than a true treatment effect
